key: cord-0866965-ha01r58d authors: Philips, Cyriac Abby; Kakkar, Kamna; Joseph, Moby; Yerol, Praveen Kumar; Ahamed, Rizwan; Rajesh, Sasidharan; Augustine, Philip title: Critically Ill COVID-19 Patient with Chronic Liver Disease - Insights into a Comprehensive Liver Intensive Care date: 2021-08-28 journal: J Clin Transl Hepatol DOI: 10.14218/jcth.2020.00110 sha: eca0e1f867439e4d7ee39203dcf97c8530307814 doc_id: 866965 cord_uid: ha01r58d The novel coronavirus-related coronavirus disease 2019 (COVID-19) pandemic has been relentless in disrupting and overwhelming healthcare the world over. Clinical outcomes of COVID-19 in patients with chronic comorbidities, especially in those with metabolic syndrome, are well documented. Chronic liver disease and cirrhosis patients are a special sub-group, among whom the management of COVID-19 is challenging. Understanding the pathophysiology of COVID-19 in patients with cirrhosis and portal hypertension improves our identification of at-risk patients for disease progression that will further help compartmentalize generalized and specialized treatment options in this special patient group. In this exhaustive review, we critically review the impact of COVID-19 on the liver and in chronic liver disease and cirrhosis patients. We further discuss common features associated with the pathophysiology of COVID-19 and cirrhosis, based on the renin-angiotensin system and deliberate current literature on guidelines for the treatment of COVID-19 and extrapolate the same to the cirrhosis population to provide a concise and stepwise, evidence-based management for cirrhosis patients with severe and critical COVID-19. There are no specific management guidelines for cirrhosis patients with COVID-19 and current recommendations for treatment are as per guidelines for general population. Nevertheless, specific issues like avoiding corticosteroids in decompensated patients with variceal bleeding, suspected sepsis, high grade hepatic encephalopathy and acute kidney injury, use of early mechanical ventilation strategies in those with severe ascites and hepatopulmonary syndrome, avoidance of remdesivir in advanced liver disease, and application of liver-specific severity scores for prognostication and identification of futility need to be highlighted. The novel coronavirus-related coronavirus disease 2019 (COVID- 19) pandemic has been relentless in disrupting and overwhelming healthcare the world over. Clinical outcomes of COVID-19 in patients with chronic comorbidities, especially in those with metabolic syndrome, are well documented. Chronic liver disease and cirrhosis patients are a special subgroup, among whom the management of COVID-19 is challenging. Understanding the pathophysiology of COVID-19 in patients with cirrhosis and portal hypertension improves our identification of at-risk patients for disease progression that will further help compartmentalize generalized and specialized treatment options in this special patient group. In this exhaustive review, we critically review the impact of COV-ID-19 on the liver and in chronic liver disease and cirrhosis patients. We further discuss common features associated with the pathophysiology of COVID-19 and cirrhosis, based on the renin-angiotensin system and deliberate current literature on guidelines for the treatment of COVID-19 and extrapolate the same to the cirrhosis population to provide a concise and stepwise, evidence-based management for cirrhosis patients with severe and critical COVID-19. There are no specific management guidelines for cirrhosis patients with COVID-19 and current recommendations for treatment are as per guidelines for general population. Nevertheless, specific issues like avoiding corticosteroids in decompensated patients with variceal bleeding, suspected sepsis, high grade hepatic encephalopathy and acute kidney injury, use of early mechanical ventilation strategies in those with severe ascites and hepatopulmonary syndrome, avoidance of remdesivir in advanced liver disease, and application of liver-specific severity scores for prognostication and identification of futility need to be highlighted. The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), an enveloped, positive single-stranded large RNA virus belonging to the beta-CoV family, is the causative agent of the current pandemic, the coronavirus disease 2019 , that has affected developed and developing countries worldwide. Even though the welldescribed and reported initial clinical sign of COVID-19 is pneumonia (fever, cough, and shortness of breath), further studies have shed light on the variable presentations and clinical outcomes in affected patients. This spectrum was found to include asymptomatic carriers, patients with gastrointestinal system predominant symptoms (nausea, diarrhea), those with anosmia and dysgeusia, and symptomatic hypercoagulable states affecting multiple organs and immune-mediated organ involvement such as vasculitislike syndromes. 1 The majority of transmissions occur via coughing and sneezing, through respiratory droplets with particle size >5-10 µm, and through the fecal-oral route. Asymptomatic COVID-19 contributes up to 80% of trans-mission, primarily limited to family members, healthcare professionals, and others with close contacts (6 feet, 1.8 meters) within closed-space public gatherings. 2 Initial studies have shown that the incubation time is between 3 to 7 days and the basic reproduction number (R0 or R naught) is 2.2. 3 The viral infection starts with the glycoprotein spike receptor-binding protein, which allows viral attachment to the angiotensin-converting enzyme receptor type 2 (ACE2) in the lungs and other tissues as well. A polybasic amino acid site in the spike protein is functionally processed by the human protease enzyme furin, which further allows exposure of the integrated sequences, resulting in a fusion of the viral and cell membranes and subsequent virus passage into the primary cell. 4 Around 97.5% of symptomatic presentations will occur within 11.5 days of infection and the median time from symptom onset to hospital admission is 7 days. The median age of hospitalized patients varies between 47 and 73 years, with male preponderance. Overall, a quarter of infected patients have comorbidities but among hospitalized COVID-19 patients, approximately 60% to 90% have comorbidities. 5, 6 The most common chronic conditions include hypertension and cardiovascular disease, diabetes, chronic kidney disease, and chronic lung disease. Clinical complications leading to morbidity and mortality include hypoxemic lung failure, myocarditis, cardiomyopathy, ventricular arrhythmias, and hemodynamic instability, stroke and rarely encephalitis, secondary bacterial sepsis, and arterial and venous thromboembolic events, the latter notable in up to 60% of those admitted to the intensive care unit (ICU). [4] [5] [6] [7] In this review, we discuss the impact of COVID-19 on the liver, focus on key aspects of disease pathogenesis and outcomes in patients with pre-existing liver disease, and discuss current evidence-based treatment protocols and exhaustive algorithms for the management of COVID-19 in cirrhosis. The Chinese Centers for Disease Control described three clinical classifications of COVID-19 based on pulmonary symptoms, classified as mild to moderate, severe, and critical disease. Patients with severe pneumonia can develop acute respiratory distress syndrome (ARDS) classified as mild, moderate, and severe depending on clinical and ventilatory criteria. Severe disease is also identified when computed tomography of the chest reveals lung infiltrates >50% within 24 to 48 h, or in the presence of septic shock or multiple organ failure (Fig. 1) . ACE2, the host cell receptor for SARS-CoV-2, is present on type 2 alveolar cells and in the gastrointestinal tract and the liver. In the liver, ACE2 is highly expressed in the endothelial layer of small blood vessels and absent in the sinusoidal endothelium and is also expressed greater in cholangiocytes than in hepatocytes. 4 Multiple studies have shown that index presentation with gastrointestinal symptoms was notable in approximately 19.6% to 73.0% of patients with SARS-CoV. Similarly, 3% to 79% of those with SARS-CoV-2 infection presented gastrointestinal predominant symptoms in various studies. [8] [9] [10] [11] Abnormal liver tests have been reported in approximately 19-76% of patients with COVID-19. It is now clear that elevated liver biochemistries are predominantly associated with severe and critical COVID-19 due to multifactorial reasons, such as druginduced liver test abnormalities, liver involvement in critical illness, and hypoxic insults. [12] [13] [14] [15] Even though ACE2 receptors are more greatly expressed in cholangiocytes, the principal pattern of liver test abnormality demonstrated in COVID-19 is of the hepatocellular type, with elevation in aminotransferases rarely above 5-times the upper limit of normal in those with and without pre-existing liver disease. 16, 17 Direct cytopathic effects of SARS-CoV-2 on hepatocytes remain unconfirmed, and liver test abnormalities are mostly related to multisystem involvement associated with severe disease, multifactorial, and secondary to systemic inflammation, immune-mediated injury, microvascular thrombosis, drug toxicity, hepatic congestion, and intercurrent sepsis. 18, 19 Post-mortem liver biopsy studies have shown non-specific features, such as focal or mild to moderate macro/microvesicular steatosis, mild portal and lobular inflammation, and sinusoidal dilatation. The direct viral cytopathic effect, viral nucleic acid, or demonstrable replication has not been demonstrated consistently across studies. Acute liver failure due to COVID-19 is not described. However, concomitant hepatotoxic drug use, including complementary and alternative medications in patients with COVID-19 with a predisposition to acute severe liver injury, could lead to acute liver failure, independent of the primary infection, and should be kept in mind with patients presenting with liver failure. 20,21 To understand the outcomes associated with COVID-19 in patients with CLD, an understanding of the common pathophysiology that plays an important role in the causation and progression of these conditions, attributable to the renin-angiotensin system (RAS), is pertinent. RAS activity starts with the breakdown of angiotensinogen (derived from the liver) by circulating renin (from the juxtaglomerular apparatus of the kidney) to form angiotensin I (Ang I). In the classical pathway, ACE in pulmonary capillaries converts Ang I to angiotensin II (Ang II), which then binds to angiotensin II type 1 receptor (AT1) that, in effect, causes vasoconstriction, is trophic, enhances fibrogenesis, increases sodium reabsorption, and is pro-inflammatory and prothrombotic. In the alternate RAS, ACE2 degrades Ang II to the peptide Ang1-7, which then acts through the mas receptor that promotes vasodilation, is anti-trophic and anti-fibrotic, promotes natriuresis, and is anti-inflammatory and anti-thrombotic. 22 In CLD, the classical pathway and its activation contributes to inflammation and fibrosis, while the alternative pathway is up-regulated to counterbalance the harmful effects. As fibrosis worsens, ACE levels and AT1 gene expressions rise, coinciding with an up-regulation in ACE2 and mas expression, increasing in both Ang 1-7 and Ang II. Cirrhotic livers have enhanced capacity to convert Ang II to Ang 1-7, which has been shown to have beneficial effects on liver fibrosis and inflammation. In late-stage cirrhosis, sympathetic nervous system activation, acetylcholine-mediated vasodilation, increased production of dysfunctional nitric oxide (NO), secretion of antidiuretic hormone, central hypovolemic status, and worsening peripheral and splanchnic vasodilation due to high Ang 1-7 renders early beneficial effects of the alternate RAS pathway redundant. [23] [24] [25] In chronic inflammation, Ang II expression activates hepatic stellate cells that drive the pathogenesis of portal hypertension. With cirrhosis progression, intrahepatic resistance increases, leading to systemic and splanchnic vasodilation and hypo-responsiveness to vasoconstrictors. 26 Thus, there is a clear change in modus operandi in the RAS-mediated pathophysiology of cirrhosis and its progression. In patients with cirrhosis and COVID-19, SARS-CoV-2 overwhelms the ACE2 receptors, resulting in the functional inhibition of the alternate RAS pathway, leading to reduced expression of Ang 1-7 (increasing proinflammatory cytokines such as interleukin (IL)-6, IL-1β and tumor necrosis factor-alpha (TNF-α) and paving the way for harmful consequences via the AT1 receptor) within the liver microenvironment and other systems. 27, 28 However, in stable cirrhosis, in the presence of highly up-regulated ACE2 receptors and higher expression of Ang 1-7, SARS-CoV-2 infection may not be uncontrollably detrimental and could be associated with better outcomes. 29 In decompensated cirrhosis, chronic activation of RAS and sympathetic nervous system activation and secretion of antidiuretic hormones occur in the presence of persistent arterial hypotension. COVID-19 can worsen the already perturbed portosystemic hemodynamics through the overwhelming use of ACE2 receptors, increasing Ang 1-7, which leads to worsening systemic and splanchnic vasodilation. Furthermore, cirrhosis is a state of chronic systemic inflammation, immunomodulation, endotoxemia, and hemodynamic alterations that promote subclinical dysfunction in most organ systems that worsen with increasing cirrhosis stages. [30] [31] [32] [33] Hence, from our understanding of pathophysiology, it is safe to assume that COVID-19 in cirrhosis is associated with different clinical outcomes, depending on the stages of liver disease and degree of portal hypertension (Fig. 2) . Worsening of pre-existing liver injury is an important clinical aspect of COVID-19. In this regard, new-onset or worsening thrombocytopenia, coagulation tests, and hypoproteinemia or low albumin could be considered part of progression in the multisystem involvement of the primary infection or worsening of the pre-existing liver disease. [34] [35] [36] The novel coronavirus itself does not cause acute severe liver injury or trigger liver failure. 20, 21 Nonetheless, COV-ID-19 in patients with pre-existing liver disease, such as alcohol-related or nonalcohol-related fatty liver, early and advanced hepatic fibrosis (CLD), cirrhosis with or without portal hypertension (clinically significant [defined as hepatic venous pressure gradient ≥10 mmHg] or otherwise) can present with acute hepatitis with or without jaundice and rarely cholestatic liver injury, acute decompensation of cirrhosis and acute-on-chronic liver failure (ACLF) due to severity of infection and subsequent treatment interventions. A recent meta-analysis on 2,034 adult individuals with a median age of 49 years found that the overall prevalence of CLD at admission was 3%. 37 In a narrative review, Garrido and colleagues, 38 based on published evidence, presumed that patients with CLD were not at greater risk for acquiring the infection. Still, those with compensated advanced and decompensated cirrhosis, hepatocellular carcinoma, nonalcoholic fatty liver disease (due to associated metabolic syndrome), autoimmune liver diseases, or a liver transplant may have a greater risk for severe COVID-19. In a small series of patients with liver disease, Ji et al. 39 showed that disease progression was higher in COVID-19 patients with CLD than in those without CLD, with the risk of developing ACLF that portend a worse prognosis. In a retrospective study from Wuhan, China, investigators found that COVID-19 patients with CLD had a longer length of stay in hospital but with mild liver injuries and higher mortality (in the presence of decompensation) than in those without CLD. The neutrophil-tolymphocyte ratio significantly predicted in-hospital death. 40 Another systematic review and meta-analysis that included 74 clinical studies demonstrated that the prevalence of CLD among all COVID-19 patients was approximately 3%. This proportion was similar in COVID-19-positive and -negative population, but CLD was significantly associated with more severe COVID-19 infection and overall mortality. 41 In Italian multicenter retrospective studies, Iavarone et al. 42, 43 showed that COVID-19 was associated with deterioration in liver function and increased mortality in the elderly with cirrhosis compared to a historically-matched group of patients with bacterial sepsis. The severity of lung and liver disease scores according to the Chronic Liver Failure-Consortium (commonly known as CLIF-C)-Organ Failure (>9), CLIF-C-ACLF ≥70 and Model for End-stage Liver Disease (commonly known as MELD; >15) independently predicted mortality. Notably, ACLF was not the cause of death in most patients but respiratory failure was in 71%. 42, 43 An international registry's preliminary results included 103 cirrhosis patients from 21 countries and four continents (60% male, median age 61 years, most common liver etiology being non-alcoholic fatty liver disease or NAFLD). Among patients analyzed from combined registries, 38% decompensated during their disease course (worsening ascites, encephalopathy, or acute kidney injury) due to COVID-19. Mortality in this group was far more than that noted with cirrhosis in the pre-COVID-19 era. However, the cause of death was lung failure in approximately 80% and liver-related in 12% (CLD without cirrhosis 12.2%, 28 days-old) with estimated glomerular filtration rate <30 mL/m or with serum creatinine ≥1 mg/dL, unless the potential benefit outweighs the potential risk. 60, 61 Thus, remdesivir has the potential to cause pulmonary, hepatic, and renal toxicity in predisposed individuals. WHO pharmacovigilance noted a disproportionately high number of reports of liver injuries and renal toxicities among patients receiving remdesivir compared with that among patients receiving other drugs for COVID-19, and the European Medicines Agency initiated a review of patients on remdesivir with acute kidney injuries. 61 other hand, short courses of corticosteroids, including dexamethasone, are safe and efficacious in acute and chronic hepatocellular or cholestatic inflammatory diseases of the liver, including reactivation of viral hepatitis, severe druginduced liver injury, ACLF, severe alcohol-related hepatitis and also in advanced decompensation associated with relative adrenal insufficiency. [63] [64] [65] However, one must be cautious in patients with decompensated cirrhosis and those with advanced liver failure, such as higher grades of ACLF and CLD patients with uncontrolled metabolic syndrome, in whom steroid use can lead to de novo or worsening bacterial or fungal infections. Hydrocortisone use in the non-cirrhosis septic shock population has been shown to improve short outcomes, such as shorter vasopressor therapy, mechanical ventilation, and length of ICU stay. 66 Higher and longer duration of steroid use can also lead to delirium and precipitate hepatic encephalopathy in patients with multiple decompensations at baseline or those who develop decompensation during COVID-19. 67-69 Guidelines at the national level from different regions/countries recommend using multiple other drugs in tandem with a universally-accepted protocol for COVID-19 treatment. However, the evidence to use these medications and adjuvant treatments is currently lacking in literature or has been confirmed to have no benefit and is not recommended for use in the treatment of COVID-19. These include hydroxychloroquine or chloroquine with or without azithromycin, ivermectin, lopinavir/ritonavir, and other protease inhibitors, favipiravir, interferon therapy, interleukin inhibitors (tocilizumab and tocilizumab), kinase inhibitors, COVID-19 convalescent plasma, intravenous immunoglobulin G specific and non-specific to SARS-Cov-2, mesenchymal stem cells, vitamin C and zinc. [70] [71] [72] [73] [74] Chloroquine/hydroxychloroquine have likelihood score D for liver toxicity and are possible rare causes of clinically apparent liver injury. In patients with porphyria cutanea tarda, high doses of hydroxychloroquine can trigger an acute hepatic injury associated with marked serum enzyme elevations resulting from an increased excretion of porphyrins. Both, but more commonly chloroquine, have been associated with life-threatening cardiac events, including arrhythmias and conduction disorders, such as QT prolongation. A majority of cirrhosis patients have subclinical cardiomyopathy. [75] [76] [77] Hence, the use of chloroquine derivatives needs caution, especially when combined with another drug, such as fluoroquinolones that may precipitate adverse cardiac events. Azithromycin is well known to cause clinically apparent liver injury in the form of acute, transient, or asymptomatic elevation in serum aminotransferases, which occurs in 1% to 2% of patients treated for short periods. 78 High-dose vitamin C resulting in high circulating concentrations, may affect the accuracy of point-of-care glucometers in assessing glycemic status in the ICU. 79 Interferons are unsafe in advanced cirrhosis, and portal hypertension and interleukin inhibitors are not well studied in cirrhosis, and hence their use should be strictly compartmentalized to research protocols. Even though zinc supplementation has not been shown to have beneficial disease-modifying properties in COVID-19, a recent meta-analysis demonstrated mild benefits in reducing hepatic encephalopathy. It may be considered an adjuvant to the standard of care in patients with cirrhosis and COVID-19 with hepatic encephalopathy. 80 Plasma and other blood product transfusions have detrimental effects in patients with cirrhosis and portal hypertension. Hence, transfusions must be curtailed in the absence of evidentiary proof for utility. 81 The benefits of vitamin D supplementation in COVID-19 patients remain to be determined. However, in those with insufficient levels (such as cirrhosis), supplementation therapy can be considered as per recommended guidelines. Nonetheless, whether this would benefit clinical outcomes in COVID-19 warrants further study. 82 A large body of published evidence suggests thrombotic events' central role in negative outcomes in patients with severe and critical COVID-19. In this regard, current recommendations for venous thromboembolism prophylaxis should be followed as per the standard of care for hospitalized adults. However, in cirrhosis, in those who have bled from varices or have variceal bleeding or are at high risk for variceal bleeding, anticoagulation use needs caution and must be tailored on a case basis. In this regard, newer diagnostic point-of-care modalities to assess the coagulation state, such as thromboelastography (i.e. TEG™) or rotational thromboelastometry (i.e. ROTEM®), could help guide prophylactic anticoagulation in patients with cirrhosis. [83] [84] [85] [86] Supportive treatment for severe or critically ill COV- Norepinephrine is the first-choice vasopressor for cirrhosis patients with shock, as per standard recommendations followed in patients with septic shock. Additionally, terlipressin may be considered as it has shown benefits for acute variceal bleeding and kidney injury. The use of dopamine in cirrhosis is not recommended, due to the high risk of inducing arrhythmias, and dobutamine is recommended only in patients with clinically significant myocardial dysfunction. Applications of intravenous human albumin in cirrhosis with sepsis, acute kidney injury, hepatic encephalopathy, and hypotension have been well documented in the literature. Adjuvant use of intravenous human albumin is recommended in severe and critically ill cirrhosis patients, in the absence of absolute contraindications for use. In cirrhosis, profound distributive shock leads to the development of refractoriness towards inotropes and pressors. In such a situation, the use of methylene blue has been shown to reduce the requirement of inotropes and could potentially be used as a salvage option. Methylene blue has also been hypothesized as an inhibitor of NO with antagonistic effects on bradykinin that could improve oxygenation at the pulmonary level in patients with COVID-19. However, with regards to methylene blue, further clinical studies are required to confirm this proposal. 70, 71, [87] [88] [89] [90] For patients with acute hypoxemic respiratory failure despite conventional oxygen therapy, high-flow nasal cannula oxygen is preferred over noninvasive positive pressure ventilation. However, in patients with severe hepatopulmonary syndrome, the latter may be considered in a well-controlled environment. 91 With high-flow nasal cannula, to optimize the alveolar recruitment, improve dead-space carbon dioxide washout as well as the positive end-expiratory pressure or to reduce airway resistance, it is prudent to initiate flow at 60 L/m, especially in situations of acute respiratory failure. In patients with hypoxemic respiratory failure and those with hypercapnia, targeted oxygen saturation should be in the range of 94-98% in the former and 88-92% in the latter. Cirrhosis patients with overt hepatic encephalopathy with a high risk of aspiration and those with hemodynamic instability should be excluded from high-flow nasal cannula use as risks outweigh benefits, including delay in early intubation. 92 For COVID-19 patients with persistent hypoxemia despite incremental oxygen supplementation, endotracheal intubation is not otherwise indicated; a trial of awake prone positioning to improve oxygenation is recommended. However, this strategy can be difficult to pursue in decompensated cirrho-sis patients who have ascites or hydrothorax. Awake prone positioning as rescue therapy for refractory hypoxemia to avoid intubation is not recommended, and early intubation should be considered in such situations, especially in cirrhosis. In cirrhosis, sedation choice in such circumstances should ideally include medications with short half-lives, such as propofol and remifentanil, with avoidance of benzodiazepines. Dexmedetomidine was well tolerated in patients with liver disease who received the medication for more than 48 h. Nonetheless, patients with liver disease required more time before extubation after drug discontinuation. 93 For mechanically ventilated adults with COVID-19 and ARDS, low tidal volume ventilation (4-8 mL/kg of predicted body weight) is recommended. In those with refractory hypoxemia, despite optimized ventilation, prone positioning for 12 to 16 h per day is suggested. Inhaled pulmonary vasodilator as rescue therapy if no rapid improvement in oxygenation is suggested if optimized ventilation and other rescue strategies do not resolve hypoxemia. The routine use of extracorporeal membrane oxygenation (ECMO) for patients with COVID-19 and refractory hypoxemia in this situation is controversial, and no recommendation can be made. In patients with cirrhosis and ARDS with life-threatening hypoxemia and hepatopulmonary syndrome, anecdotal reports have shown the benefits of using ECMO, even as a bridge to liver transplantation. Nonetheless, liver tests, especially bilirubin and alkaline phosphatase levels, were found to predict poor outcomes post-ECMO in cardiac surgery patients. Hence, advanced cirrhosis patients may not be ideal candidates for ECMO in critical COVID-19. The use of ECMO also can lead to an elevation in liver enzymes. Further to this, a nationwide population-based cohort study on the outcome of ECMO support in patients with liver cirrhosis showed that its utility for cirrhosis patients, especially when >2 risk factors (age ≥65 years, those with underlying respiratory disease, hypoalbuminemia, and liver transplant receipt) have been identified, was deleterious on clinical outcomes. [94] [95] [96] [97] In case staged upgraded medical interventions fail to improve hypoxemic respiratory failure, then ECMO may be considered on a case-by-case basis and following inclusion as per EOLIA trial criteria, which include one of the following: a ratio of the partial pressure of arterial oxygen (Pao2) to the fraction of inspired oxygen (Fio2) of less than 50 mmHg for more than 3 h or Pao2:Fio2 of less than 80 mmHg for more than 6 h or an arterial blood pH of less than 7.25 with a partial pressure of arterial carbon dioxide of at least 60 mmHg for more than 6 h. Even though the early use of ECMO does not significantly improve mortality at 60 days in patients with severe ARDS, it might help improve short-term survival when used as a rescue modality. 98 For critically ill patients with COVID-19 who have acute kidney injury and develop indications for renal replacement therapy, continuous renal replacement therapy is recommended. In its absence, prolonged intermittent renal replacement therapy holds for those with cirrhosis and advanced liver failure. 99, 100 At present, for patients with COVID-19 and severe or critical illness, empiric broad-spectrum antimicrobial therapy in the absence of another indication is not recommended. However, in the cirrhotic population, especially among those with decompensation such as variceal bleeding or those with ACLF, early empirical antibiotics may be considered since the patients are at high risk of developing hospital-acquired infections and secondary bacteremia. [101] [102] [103] An exhaustive algorithm for the management of cirrhosis patients with COVID-19 is shown in Figure 3 . The incidence of COVID-19 among patients with cirrhosis may be low but further studies are required to address this topic clearly. The novel coronavirus does not cause direct liver injury or promote liver failure, but severe infections can result in unstable decompensation of cirrhosis and ACLF. COVID-19 in decompensated cirrhosis and in conditions that lead to ACLF are associated with poor clinical outcomes, even though the most common cause for mortality is lung failure and not progressive liver dysfunction. Current recommended treatment guidelines, such as use of corticosteroids appear to be safe in patients with stable cirrhosis, while caution must be exerted towards experimental and nonevidence-based treatments in this special patient population, especially in patients with decompensated cirrhosis with secondary sepsis and those with ACLF. Physician-driven use of experimental methods or therapeutics within clinical research must be guided by its safety in the liver disease population. Critical care management of severe COVID-19 in cirrhosis should be on similar lines as in the general patient population but with the use of specific therapies beneficial in cirrhosis, such as intravenous human albumin and terlipressin. Early recognition of those at risk for worse outcomes is imperative for imparting beneficial critical care management in cirrhosis. None to declare. Cyriac Abby Philips is an editorial member, academic editor and guest editor of the special issue on COVID-19 and the Liver in the Journal of Clinical and Translational Hepatology. The other authors have no conflict of interests related to this publication. One disease, many faces-typical and atypical presentations of SARS-CoV-2 infection-related COVID-19 disease An overview of COVID-19 The reproductive number of COVID-19 is higher compared to SARS coronavirus SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19) COVID-19: Characteristics and therapeutics The importance of understanding the stages of COVID-19 in treatment and trials Immune response, inflammation, and the clinical spectrum of COVID-19 COVID-19 pandemic-a focused review for clinicians Impact of COVID-19: perspectives from gastroenterology The digestive system and the COVID-19 COVID-19 and the gastrointestinal tract: more than meets the eye Systematic review with meta-analysis: liver manifestations and outcomes in COVID-19 COVID 19 and liver: An A-Z literature review COVID-19 and the liver: little cause for concern Gastrointestinal and liver manifestations of COVID-19 The hallmarks of COVID-19 disease Abnormal liver function tests in patients with COVID-19: Relevance and potential pathogenesis COVID-19 and liver dysfunction: Current insights and emergent therapeutic strategies The liver in times of COVID-19: What hepatologists should know SARS-CoV-2 related liver impairment -perception may not be the reality Letter to the Editor: Coronavirus disease 2019-related liver injury and clinical outcomes: Does it really exist? Liver injury in COVID-19: The current evidence Splanchnic vasodilation and hyperdynamic circulatory syndrome in cirrhosis Vascular pathobiology in chronic liver disease and cirrhosis -current status and future directions Physiopathology of splanchnic vasodilation in portal hypertension COVID-19 and liver disease: An update COVID-19 and the renin-angiotensin system (RAS): A spark that sets the forest alight? Covid-19: the renin-angiotensin system imbalance hypothesis Viral replication of SARS-CoV-2 could be self-limitative -The role of the renin-angiotensin system on COVID-19 pathophysiology The ACE-2 in COVID-19: Foe or friend? Liver disease and the reninangiotensin system: recent discoveries and clinical implications Renin angiotensin system in liver diseases: Friend or foe? Role of the renin-angiotensin system in hepatic fibrosis and portal hypertension Sepsis and septic shock Sepsis and septic shock Acute-on-chronic liver failure vs. traditional acute decompensation of cirrhosis Coronavirus disease 2019 and prevalence of chronic liver disease: A meta-analysis Review article: COVID-19 and liver diseasewhat we know on 1st Effect of COVID-19 on patients with compensated chronic liver diseases Clinical characteristics of chronic liver disease with coronavirus disease 2019 (COVID-19): a cohort study in Wuhan Prevalence of chronic liver disease in patients with COVID-19 and their clinical outcomes: a systematic review and meta-analysis High rates of 30-day mortality in patients with cirrhosis and COVID-19 High rates of 30-day mortality in patients with cirrhosis and COVID-19 High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: Preliminary results from an international registry Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study) Impact of COVID-19 on the care of patients with liver disease: EA-SL-ESCMID position paper after 6 months of the pandemic Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort Therapeutic management of adults with COVID-19 Dexamethasone in hospitalized patients with Covid-19 Remdesivir for the treatment of Covid-19 -Final report Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: A meta-analysis World Health Organization. Corticosteroids for COVID-19 Repurposed antiviral drugs for Covid-19 -Interim WHO solidarity trial results Remdesivir: A review of its discovery and development leading to emergency use authorization for treatment of COVID-19 Compassionate use of remdesivir for patients with severe Covid-19 Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial Liver injury in remdesivir-treated COVID-19 patients Drug-induced liver injury in a patient with coronavirus disease 2019: Potential interaction of remdesivir with P-Glycoprotein inhibitors Remdesivir in patients with acute or chronic kidney disease and COVID-19 Descriptive analysis of COVID-19-related spontaneous reports from VigiBase: interim results The management of glucocorticoid therapy in liver failure Favorable effect of corticosteroids in treating acute-on-chronic liver failure underlying chronic hepatitis B Severe alcoholic hepatitis: current perspectives Hydrocortisone in septic shock: all the questions answered? Sepsis in alcohol-related liver disease Glucocorticoids and non-alcoholic fatty liver disease Update on diagnosis and management of sepsis in cirrhosis: Current advances COVID-19 treatment guidelines evaluation, and treatment of coronavirus (COVID-19). In: StatPearls Treasure Island (FL): StatPearls Publishing COVID-19: A review of the proposed pharmacological treatments Immune-mediated approaches against COVID-19 Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial) Cardiopulmonary dysfunction in cirrhosis Cirrhotic cardiomyopathy: A new clinical phenotype Redefining cirrhotic cardiomyopathy for the modern era Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases The effects of intravenous vitamin C on point-of-care glucose monitoring Role of zinc supplementation in the management of chronic liver diseases: A systematic review and meta-analysis Transfusion strategies in patients with cirrhosis Vitamin D-related immunomodulation in patients with liver cirrhosis Venous thromboembolism complicated with COVID-19: What do we know so far? Coagulation, hemostasis, and transfusion during liver transplantation Rotational thrombelastometry (ROTEM) improves hemostasis assessment compared to conventional coagulation test in ACLF and Non-ACLF patients Thromboelastometry in patients with advanced chronic liver disease stratified by severity of portal hypertension Care of critically ill patients with COVID-19 A randomized trial comparing terlipressin and noradrenaline in patients with cirrhosis and septic shock Terlipressin is superior to noradrenaline in the management of acute kidney injury in acute on chronic liver failure Application of methylene blue -vitamin C -N-acetyl cysteine for treatment of critically ill COVID-19 patients, report of a phase-I clinical trial Immediate noninvasive ventilation may improve mortality in patients with hepatopulmonary syndrome after liver transplantation High-flow nasal cannula oxygen in adults: An evidence-based assessment 36th International Symposium on Intensive Care and Emergency Medicine Liver function predicts survival in patients undergoing extracorporeal membrane oxygenation following cardiovascular surgery Extracorporeal membrane oxygenation as a bridge to liver transplantation for acute respiratory distress syndrome-induced life-threatening hypoxaemia aggravated by hepatopulmonary syndrome Altered liver function in patients undergoing veno-arterial extracorporeal membrane oxygenation (ECMO) therapy Outcome of extracorporeal membrane oxygenation support in patients with liver cirrhosis: a nationwide population-based cohort study EOLIA trial: the future of extracorporeal membrane oxygenation in acute respiratory distress syndrome therapy? Breathe (Sheff) Prognosis of patients with cirrhosis and aki who initiate RRT Continuous renal replacement therapy in critically ill patients with acute on chronic liver failure and acute kidney injury: A retrospective cohort study Antibiotic prophylaxis in cirrhosis: Good and bad Prophylactic antibiotics in cirrhosis: Are they promoting or preventing infections? Challenge to the intestinal mucosa during sepsis